GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines.
Since May 10, 2013, the stock price has climbed 1,033%.
And there are even more gains ahead in the next year as the company receives approval to launch cannabis-based medicine.
One of its products, Sativex, is an oromucosal spray that’s a formulated extract of the cannabis sativa plant.
According to GW’s website, the biopharmaceutical firm is commercializing Sativex for MS in 16 countries outside of the United States.